About us

Ascenion is an independent technology transfer company focussing on the life sciences.

We work closely with 28 European public research institutions to ensure that promising scientific findings are identified, secured and brought to market to the benefit of society. On average, we evaluate 100 invention disclosures per year, handle 60 patent applications and negotiate some 80 revenue-generating cooperation and licensing agreements with industry. Moreover, we guide and support spin-offs on the road to independence. Currently, we hold equity in 21 of these companies. All this helps create innovative products and jobs in growth sectors.

We offer access to more than 700 commercial opportunities. The portfolio includes potential therapeutics and diagnostics addressing a broad range of diseases, as well as medical device technologies, platform technologies and software.

Products and services

We are looking for licensing and cooperation partners for our technologies: http://www.ascenion.de/en/technology-offers 

Ascenion GmbH
Herzogstr. 64
80803 Munich

Phone: +49 89 3188140
Fax: +49 89 31881420
Internet: www.ascenion.de
E-mail: Send message

Contact person

Esther Lange
Industry Liaison Manager
Phone: +49 89 31881422
E-mail: Send message

News & Innovations

12th BioVaria brings academia and industry together

13 May 2019, Munich, Germany – The 12th BioVaria welcomed over 250 life-science innovators to Munich, including biopharma executives, investors, academic inventors, entrepreneurs and technology transfer experts. There were 67 peer-selected licensing opportunities on offer, originating from as many research institutes, universities and university hospitals from all over Europe. In addition, 17 start-ups were featured. Participants actively engaged in technology discussions, competitions and panels, and numerous one-on-ones were held to initiate collaborations.

The winners of this year’s ‘Startup Pitch & Partner Competition’ are ISD Immunotech, in the category ‘Emerging’, and Mindpax.me, in the category ‘Rising’. They were selected by a jury of first-tier venture capitalists for their outstanding presentations, their promising technologies and their business concepts. ISD Immunotech, a spin-out from Aarhus University, Denmark, pursues a novel approach for the treatment of severe SLE (systemic lupus erythematosus), an autoimmune disease that so far lacks specific treatment options. Mindpax.me develops a digital solution for monitoring individual biorhythms to help prevent mental health attacks. It holds strong potential to improve quality of life for millions of patients, while considerably reducing healthcare costs. ‘We are delighted to accept the Biovaria Emerging Startup award. It will help us attract the recognition and financing required to develop the first safe and effective therapy for lupus patients,’ said Tara Heitner, CEO of ISD. Pavel Nevický, co-founder of Mindpax.me continued: ‘We are honoured to be chosen best Rising Startup at BioVaria, and the award strengthens our determination to apply digital diagnostic tools to the treatment of severe mental health disorders.’

This year’s panel brought together leading players from academia and industry to evaluate the current state and prospects of stem cell research and therapy. The panellists discussed the opportunities and particular challenges encountered in development and clinical use, and highlighted the technological progress that has been made over the last decade. The panel agreed that stem cell based approaches will impact the future of regenerative medicine and will ultimately find their place in clinical practice over the midterm – although many difficulties remain to be solved. Given the inherent complexity of the field, they suggested a cross-disciplinary approach with all stakeholders working hand-in-hand, right from the beginning.

New this year was a satellite event sponsored by ISAR Bioscience. Academic scientists with pioneering translational projects in the field of stem cell medicine were invited to present their work confidentially to seasoned experts and compete for the ISAR Biosciences award. The winner is Dr Sarah-Christin Staroßom from Charité – Universitätsmedizin Berlin. She was honoured for her groundbreaking research on remyelination, that aims to identify key regenerative factors, biomarkers and treatment options for demyelinating diseases, including multiple sclerosis. Her project receives EUR 2,000 and will be further evaluated for ISAR project recognition and funding.

BioVaria 2019 was organized by Ascenion, together with 14 additional technology transfer organizations from five European nations.

Save the date for next year’s BioVaria in Munich: 27 – 28 April 2020.

Some of the technologies and start-ups presented during BioVaria 2019 will be available soon at www.biovaria.org


Bavarian Ministry of Economic Affairs, Regional Development and Energy

BioM, Abbvie, Else Kröner-Fresenius-Stiftung, ISAR Bioscience, Johnson & Johnson Innovation, HERTIN & Partner, Kador & Partner, Vossius & Partner

Startup Sponsors:
24IP Law Group, Accelero Bioanalytics, Charles River, German Accelerator Life Sciences, IASON Consulting, LSI Life Science Inkubator, LSP, ttopstart, TVM Capital Life Science

Technology transfer partners:
Ascenion, Austria Wirtschaftsservice Gesellschaft, BayPAT, DKFZ - German Cancer Research Center, DZIF - German Center for Infection Research, EMBLEM Technology Transfer, IOCB Tech, Lead Discovery Center, LMU Munich, Max Planck Innovation, Netval, PROvendis, TechnologieAllianz, University of Pardubice, VIS

Network partners:
ASTP-Proton, BIO Deutschland, BioRN

Communication sponsors:
Business Wire, Going Public, LABIOTECH.eu, transkript

About BioVaria

BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry.

Key features of BioVaria:

Unique gathering of Europe's top scientists, entrepreneurs, technology transfer professionals, investors and industry representatives
Presentation of more than 60 licensable technologies and startups originating from public research institutions and universities across Europe
Focus on patent-protected, commercially attractive opportunities covering therapeutics, diagnostics and research tools in the fields of cancer, infectious diseases, metabolism, autoimmune and neurodegenerative disorders, and in other disease areas
Interactive format combining 10-min oral presentations with an interactive exhibition and plenty of networking opportunities
Startup Pitch & Partner program with a competition for the BioVaria Startup Award, one-on-one mentoring and startup-investor speed dating
Panel discussion
Ample space to discuss scientific details face-to-face with the inventors and entrepreneurs
Jointly organized by Ascenion and a selected group of leading European technology transfer organizations

Further information and technologies: www.biovaria.org

Further reading
Ascenion supports collaboration agreement between HZI / HIPS and GARDP

The Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), a location of the Helmholtz Centre for Infection Research (HZI), teams up with the Global Antibiotic Research and Development Partnership (GARDP) to discover novel antibiotics. Ascenion, the HZI’s technology transfer partner, supported the deal.

The partners will focus on drug-resistant pathogens that are most threatening to public health according to WHO’s classification. HIPS will contribute its unique library of natural compounds to the global drug discovery initiative, which brings together leading institutes and public private partnerships to combat antibacterial resistance. Besides HIPS and GARDP, it embraces the open-access screening initiative CO-ADD and Calibr, the translational division of Scripps Research.

For further information see the HZI's press release

Further reading
OMEICOS starts Phase II Trial in Atrial Fibrillation

Ascenion’s portfolio company OMEICOS dosed a first patient in a Phase II clinical trial for its lead program OMT-28. The placebo-controlled, double-blind, randomized PROMISE-AF study will evaluate the efficacy and safety of the candidate in patients with persistent atrial fibrillation (AF). In total, the company expects to enrol up to 120 participants in four European countries.

OMT-28, a synthetic small molecule analogue of a natural omega-3 fatty acid metabolite, targets one of nature’s most important cell-protective pathways. If successful, it would introduce a novel treatment modality in the segment of anti-arrhythmic drugs, with potential benefits for millions of patients.

For further information see OMEICOS’ press release

Further reading

Click here if you notice an image that violates copyright or privacy rights.

Get in contact

We use cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection